0.4349
Precedente Chiudi:
$0.436
Aprire:
$0.4538
Volume 24 ore:
32,733
Relative Volume:
1.39
Capitalizzazione di mercato:
$1.96M
Reddito:
$7,500
Utile/perdita netta:
$-9.83M
Rapporto P/E:
-0.0711
EPS:
-6.1164
Flusso di cassa netto:
$-9.33M
1 W Prestazione:
-4.63%
1M Prestazione:
-13.02%
6M Prestazione:
-36.05%
1 anno Prestazione:
-66.55%
Oragenics Inc Stock (OGEN) Company Profile
Nome
Oragenics Inc
Settore
Industria
Telefono
813-286-7900
Indirizzo
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
OGEN
Oragenics Inc
|
0.4349 | 1.96M | 7,500 | -9.83M | -9.33M | -6.1164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oragenics Inc Borsa (OGEN) Ultime notizie
Oragenics (OGEN) Edges Higher as Sub-$1 Biotech Holds Near $0.50Iron Condor Alert - https://www.siam.in/
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum - GlobeNewswire
Oragenics Faces NYSE Compliance Challenges Amid Trial Progress - The Globe and Mail
Oragenics Faces Potential NYSE American Delisting on Equity Shortfall - minichart.com.sg
Oragenics Faces NYSE Compliance Challenges Amid Trial Progress - TipRanks
Oragenics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Oragenics (NYSE: OGEN) faces NYSE listing warning as equity falls short - Stock Titan
Oragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing Status - Quiver Quantitative
Oragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing Status - Quiver Quantitative
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update - GlobeNewswire
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update - Yahoo Finance
Oragenics (OGEN) Earnings Report: EPS Exceeds Its Estimate for the Current Session; Trading Response - dars.gov.et
Oragenics (OGEN) Earnings Report: EPS Exceeds Its Estimate for the Current Session; Trading Response - careplusvn.com
Oragenics (OGEN) Earnings Report: EPS Exceeds Its Estimate for the Current Session; Trading Response - www.dars.gov.et
Oragenics (OGEN) Earnings Report: EPS Exceeds Its Estimate for the Current Session; Trading Response - dars.gov.et
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineRange Breakout - vinanet.vn
Oragenics: Q2 Earnings Snapshot - AOL.com
Oragenics: Q2 Earnings Snapshot - 10TV
Oragenics (OGEN) flags going concern risk with $4.7M loss and $3.9M cash - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineRange Breakout - vinanet.vn
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineAAII Bullish - www.dars.gov.et
Oragenics (OGEN) Gains 2% as Micro-Cap Biotech Holds Key Support at $0.47Technical Analysis - vinanet.vn
Oragenics (OGEN) Gains 2% as Micro-Cap Biotech Holds Key Support at $0.47Collar Trade - dars.gov.et
OGEN Q2 2023 Earnings: Narrower EPS Beat Lifts Shares 2.0%Earnings Beat Streak - careplusvn.com
OGEN Q2 2023 Earnings: Narrower EPS Beat Lifts Shares 2.0%Interim Report - vinanet.vn
Oragenics Q2 2023 Earnings: Narrowed Loss Surprises as Operational Efficiency ImprovesEarnings Acceleration Picks - careplusvn.com
Oragenics Q2 2023 Earnings: Narrowed Loss Surprises as Operational Efficiency ImprovesEBITDA Analysis - vinanet.vn
Oragenics Q2 2023 Earnings: Narrowed Loss Surprises as Operational Efficiency ImprovesPre-Earnings Setup - dars.gov.et
Oragenics Inc. Revenue Breakdown – AMEX:OGEN - TradingView
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Cash Flow - TradingKey
OGEN|Oragenics Inc|Price:0.507|Chg%:-0.004 - TradingKey
TradingKey - TradingKey
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
OGEN Q2 2023 Earnings: EPS Surprises to the Upside Despite No RevenueRevenue Guidance Update - vinanet.vn
OGEN Q2 2023 Earnings: EPS Surprises to the Upside Despite No RevenueOperating Income Trends - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesPost-Earnings Drift - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesNew Analyst Coverage - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesFull Year Guidance - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesCost Structure Review - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesEPS Revision Trend - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesOperating Income Trends - dars.gov.et
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineBPI Bear Correction - dars.gov.et
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineVOLD Alert - careplusvn.com
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineTechnical Analysis - vinanet.vn
OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Despite Stock DeclineGuidance vs Actual - vinanet.vn
OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Despite Stock DeclineEarnings Revision Downgrade - www.dars.gov.et
Oragenics Incto Receive Exclusive License - Moomoo
Oragenics Inc Azioni (OGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oragenics Inc Azioni (OGEN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Frederick W. Telling | Director |
Dec 12 '25 |
Proposed Sale |
0.91 |
210 |
192 |
0 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):